Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial.
Brunner HI, Shmagel A, Horneff G, Foeldvari I, Antón J, Ramanan AV, Qian Y, Unnebrink K, Hao S, Camp HS, Khan N, Liu W, Mohamed MF. Brunner HI, et al. Among authors: unnebrink k. Arthritis Care Res (Hoboken). 2024 Nov 14. doi: 10.1002/acr.25465. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 39542836
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
Thaçi D, Soliman AM, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, Williams DA, Weisenseel P. Thaçi D, et al. Among authors: unnebrink k. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):1686-1691. doi: 10.1111/jdv.17109. Epub 2021 Jul 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33428281 Clinical Trial.
Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.
Thaçi D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD, Landells I, Hoeger PH, Unnebrink K, Seyger MMB, Williams DA, Rubant S, Philipp S. Thaçi D, et al. Among authors: unnebrink k. Br J Dermatol. 2019 Dec;181(6):1177-1189. doi: 10.1111/bjd.18029. Epub 2019 Jul 25. Br J Dermatol. 2019. PMID: 31017657 Free PMC article. Clinical Trial.
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Poordad F, Sedghi S, Pockros PJ, Ravendhran N, Reindollar R, Lucey MR, Epstein M, Bank L, Bernstein D, Trinh R, Krishnan P, Polepally AR, Unnebrink K, Martinez M, Nelson DR. Poordad F, et al. Among authors: unnebrink k. J Viral Hepat. 2019 Aug;26(8):1027-1030. doi: 10.1111/jvh.13109. Epub 2019 May 6. J Viral Hepat. 2019. PMID: 30980576 Free PMC article. Clinical Trial.
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.
Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T. Unkel S, et al. Among authors: unnebrink k. Pharm Stat. 2019 Mar;18(2):166-183. doi: 10.1002/pst.1915. Epub 2018 Nov 20. Pharm Stat. 2019. PMID: 30458579 Free PMC article.
Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D. Papp K, et al. Among authors: unnebrink k. Lancet. 2017 Jul 1;390(10089):40-49. doi: 10.1016/S0140-6736(17)31189-3. Epub 2017 May 4. Lancet. 2017. PMID: 28478975 Clinical Trial.
57 results